{{medical}}
{{drugbox |
|image = Aciclovir structure.svg
|image2 = Aciclovir.jpg
|width = 150
|IUPAC_name = 9-((2-羟乙氧基)-甲基)鸟嘌呤
| synonyms = acycloguanosine
| IUPHAR_ligand = 4829
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59277-89-3
| ATC_prefix = J05
| ATC_suffix = AB01
| ATC_supplemental = {{ATC|D06|BB03}} {{ATC|S01|AD03}}
| PubChem = 2022
| DrugBank_Ref = {{drugbankcite|changed|??}}
| DrugBank = APRD00567
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DB00787
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1945
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X4HES1O11F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00222
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2453
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 184
| PDB_ligand = AC2
| C=8 | H=11 | N=5 | O=3
| molecular_weight = 225.21 g/mol
| melting_point = 256.5
| bioavailability = 10–20% (口服)
| protein_bound = 9-33%
| metabolism = 病毒性胸腺嘧啶激酶
| elimination_half-life = 2.2–20 hours
| excretion = [[肾|肾]]
| pregnancy_category = B3 <small>([[Australia|Au]])</small>, B <small>([[United_States|U.S.]])</small>
| legal_status = unscheduled/S4 <small>(Au)</small>, POM <small>([[United_Kingdom|UK]])</small>
| routes_of_administration = [[intravenous|IV]], oral, topical
}}
'''阿昔洛韋'''（'''Aciclovir'''，'''ACV'''）又被寫作'''Acyclovir'''或'''Acycloguanosine'''，又称'''无环鸟苷'''，是一种[[鸟嘌呤|鸟嘌呤]]类似物类的[[抗病毒药物|抗病毒药物]]<ref>{{Cite journal|title=Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy|url=https://www.ncbi.nlm.nih.gov/pubmed/16284630|last=De Clercq|first=Erik|last2=Field|first2=Hugh J.|date=2006-01-01|journal=British Journal of Pharmacology|issue=1|doi=10.1038/sj.bjp.0706446|volume=147|pages=1–11|issn=0007-1188|pmc=1615839|pmid=16284630|access-date=2016-12-16|archive-date=2016-12-20|archive-url=https://web.archive.org/web/20161220174627/https://www.ncbi.nlm.nih.gov/pubmed/16284630|dead-url=no}}</ref>。主要用來治療[[单纯疱疹病毒|单纯疱疹病毒]]感染、[[水痘|水痘]]、[[带状疱疹|带状疱疹]]。另外也應用在移植手術後，預防[[人類疱疹病毒第四型|人類疱疹病毒第四型]]等[[巨細胞病毒|巨細胞病毒]]感染的預防性投藥。同時具有口服劑型與[[靜脈注射|靜脈注射]]劑型。<ref name=":0">{{Cite web|url=http://www.drugs.com/monograph/acyclovir.html|title="Acyclovir|accessdate=2015-01-01|author=|date=|publisher=The American Society of Health-System Pharmacists.|archive-date=2015-01-05|archive-url=https://web.archive.org/web/20150105113809/http://www.drugs.com/monograph/acyclovir.html|dead-url=no}}</ref>阿昔洛韦是最常用的抗病毒药物之一。

最常見的副作用是噁心、嘔吐。有時會造成腎臟受損或血小板低下等較嚴重的副作用。 由於藥物代謝的關係，肝腎功能較差者使用藥物時的劑量要多加注意。<ref name=":0" /> 阿昔洛韋是相對安全的婦女用藥，並未觀察到特殊的副作用。<ref name=":0" /><ref>{{Cite web|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|title=Prescribing medicines in pregnancy database|accessdate=2014-04-22|author=|date=2014-03-03|publisher=Australian Government.|archive-date=2014-04-08|archive-url=https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|dead-url=no}}</ref> 即便在[[母乳餵養|母乳餵養]]時使用也相對安全。<ref name="#1">{{Cite book|url=https://www.worldcat.org/oclc/922644939|date=2014-01-01|publisher=Jones & Bartlett Learning|chapter=Tarascon pocket pharmacopoeia 2015 deluxe lab coat edition.|oclc=922644939|title=|access-date=2016-12-16|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713084658/https://www.worldcat.org/title/tarascon-pocket-pharmacopoeia-2015-deluxe-lab-coat-edition/oclc/922644939|dead-url=no}}</ref>阿昔洛韋是一種從[[鳥苷|鳥苷]]而來的核酸衍生物，其作用原理為阻止病毒複製[[脱氧核糖核酸|脱氧核糖核酸]]。<ref name=":0" />

阿昔洛韋於1977年被發現。<ref>{{Cite book|url=https://www.worldcat.org/oclc/854681015|last=Erik,|first=De Clercq,|date=2013-01-01|publisher=Academic Press|chapter=Anti-viral agents|oclc=854681015|title=|access-date=2016-12-16|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713124826/https://www.worldcat.org/title/anti-viral-agents/oclc/854681015|dead-url=no}}</ref>阿昔洛韦曾因其极高的选择性和低细胞毒性而被视为是抗病毒治疗的新时代的开始，其发明者美国药理学家[[格特鲁德·B·埃利恩|格特鲁德·B·埃利恩]]（Gertrude Belle Elion）也部分因此而获得1988年[[诺贝尔生理学或医学奖|诺贝尔生理学或医学奖]]。阿昔洛韋也被列入[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]，是建立基礎照護系統時，最重要的必備基礎藥物之一。<ref>{{Cite web|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|title=WHO Model List of EssentialMedicines|accessdate=2014-04-22|author=World Health Organization.|date=October 2013|publisher=|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref> 目前阿昔洛韋已經是[[通用名药物|通用名药物]]，在全球有許多不同的商品名。<ref>{{Cite web|url=http://www.drugs.com/international/aciclovir.html|title=Aciclovir|accessdate=6 September 20|author=Drugs.com|date=|publisher=|archive-date=2015-09-23|archive-url=https://web.archive.org/web/20150923225253/http://www.drugs.com/international/aciclovir.html|dead-url=no}}</ref>阿昔洛韋每一劑的批發價約為0.03 到0.12美金。<ref>{{Cite web|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=ACI400T&s_year=2014&year=2014&str=400%20mg&desc=Aciclovir&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E4%2E1%2E&supplement=&class_name=%2806%2E4%2E1%2E%29Antiherpes%20medicines%3Cbr%3E|title=Aciclovir|accessdate=2015-09-06|author=International Drug Price Indicator Guide.|date=|publisher=|deadurl=yes|archiveurl=https://web.archive.org/web/20170305062222/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=ACI400T&s_year=2014&year=2014&str=400%20mg&desc=Aciclovir&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E4%2E1%2E&supplement=&class_name=%2806%2E4%2E1%2E%29Antiherpes%20medicines%3Cbr%3E|archivedate=2017年3月5日}}</ref>在美國，每劑阿昔洛韋大約0.5美金。<ref name=":0" /><ref name="#1"/>

==作用机理==
阿昔洛韦与以前的核苷类似物类抗病毒药物不同，它只含有部分的核苷结构，其[[糖环|糖环]]被一条开放链取代。阿昔洛韦可被病毒胸腺嘧啶激酶（Thymidine Kinase, TK）催化磷酸化变成一磷酸无环鸟苷（acyclo-GMP），此过程比细胞胸腺嘧啶激酶快3000多倍。在细胞酶的催化下转变成二磷酸无环鸟苷（acyclo-GDP）及三磷酸无环鸟苷（acyclo-GTP）。acyclo-GMP是一种十分有效的DNA聚合酶抑制剂，它与病毒的亲和力是细胞聚合酶的100倍。作为酶作用物，acyclo-GTP与病毒的DNA结合，导致DNA链终止。同时，病毒酶不能将acyclo-GTP从DNA链上除去，从而导致DNA聚合酶的作用被进一步的抑制。可能是因为细胞磷酸酶的作用，acyclo-GTP在细胞中的代谢相当迅速。

==副作用==
一般[[耐受性|耐受性]]良好。局部用药有其轻度刺激症状，静脉滴注外渗可引起局部炎症和[[静脉炎|静脉炎]]，还有厌食、恶心、头痛和皮症。

== 临床应用 ==
阿昔洛韦为[[HSV|HSV]]感染的首选药物。局部应用治疗疱疹性角膜炎、单纯疱疹和带状疱疹，口服或静脉注射可有效治疗单纯疱疹脑炎、生殖器疱疹、免疫缺陷病人单纯疱疹感染等。

== 參考文獻 ==
{{Reflist|2}}

==延伸閱讀==
{{refbegin|2}}
* {{Cite journal|pmid=20684612|pmc=2936711|year=2010|author1=Hazra|first1=S|title=The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): Implications for the development of dCK-activated acyclic guanine analogues|journal=Journal of Medicinal Chemistry|volume=53|issue=15|pages=5792–800|last2=Konrad|first2=M|last3=Lavie|first3=A|doi=10.1021/jm1005379}}
* Harvey Stewart C. in Remington’s Pharmaceutical Sciences 18th edition: (ed. Gennard, Alfonso R.)  Mack Publishing Company, 1990.  {{ISBN|0-912734-04-3}}.
* Huovinen P., Valtonen V. in Kliininen Farmakologia (ed. Neuvonen ''et al.'').  Kandidaattikustannus Oy, 1994.  {{ISBN|951-8951-09-8}}.
* {{cite journal |author1=Périgaud C. |author2=Gosselin G. |author3=Imbach  J.-L. | year = 1992 | title = Nucleoside analogues as chemotherapeutic agents: a review | url = | journal = Nucleosides and nucleotides | volume = 11 | issue = 2–4| page = }}
* Rang H.P., Dale M.M., Ritter J.M.: Pharmacology, 3rd edition.  Pearson Professional Ltd, 1995. 2003 (5th) edition {{ISBN|0-443-07145-4}}; 2001 (4th) edition {{ISBN|0-443-06574-8}}; 1990 edition {{ISBN|0-443-03407-9}}.
{{refend}}

==外部連結==
{{Portal|药理学}}
{{Portal|病毒}}
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Acyclovir U.S. National Library of Medicine: Drug Information Portal–Aciclovir] {{Wayback|url=http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Acyclovir |date=20160409214311 }}

{{抗DNA病毒药物}}
{{抗病毒药物}}
{{国家基本药物目录/抗微生物药}}
{{GlaxoSmithKline}}

[[Category:抗病毒药物|Category:抗病毒药物]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]